True or False: Cetuximab, a novel dosing regimen recently approved by the FDA, can be dosed alone or in combination with chemotherapy for patients with either colorectal or head and neck cancer.
The FDA has approved a higher dose of cetuximab for the treatmen of patients with KRAS wild-type, EGFR-expressing metastatic colorectal cancer or squamous cell carcinoma of the head and neck.
True or False: Several compounds found in coffee possess antioxidant, anti-inflammatory, and insulin-sensitizing effects, which may contribute to anticancer activity.
Which of the following are the 3 current modalities for rectal cancer?
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
Anlotinib was beneficial in Chinese patients with refractory metastatic CRC, and yielded particular OS improvement in those with RAS/KRAS/BRAF-wildtype disease.
Findings from a cohort study of patients with advanced or metastatic CRC showed that increased coffee consumption was linked to a lower risk for disease progression and death.
Julio Garcia-Aguilar, MD, PhD, provided insight on how nonoperative management of rectal cancer is evolving at the virtual 2020 Great Debates & Updates in Gastrointestinal Malignancies meeting.
An international study has shown that patients with colon cancer and a higher Immunoscore benefit the most from chemo in terms of recurrence risk.